Hyperprolactinaemia is one of the most common endocrinological disorder at women at the reproductive age. Prolactin is produced by the anterior lobe of the pituitary.The main role of prolactin is associated with mamotrophic action and lactogenesis. Hyperprolactinaemia causes several symptoms such as menstrual disorders, infertility, decrease of sexual function, galactorrhea in women and gynecomasty, impotence and decrease of semen quality in men. Recent studies have presented prolactin as a homone involved in many metabolic processes. Long-term consequences of high prolactin serum concentration are related to higher risk of cardiovascular system disease, disturbances in lipid profile and immunological system. Hyperprolactiaemia causes decrease of bone mass density (BMD). High serum prolactin levels lead to increase of the risk of osteopenia or/and osteoporosis. Decrease of BMD results from hypoestrogenism induced by hyperprolactinaemia and also by the direct negative influence of prolactin on bone. Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures. Important group of patients threatened by osteoporosis and bone fracture is constituted by women which use antipsychotic drugs (which induce hyperprolactinaemia). Hyperprolactinaemia diagnosed in patients should be treated as soon as possible. Hyperprolactinaemic patients should be diagnosed in the direction of osteopenia and osteoporosis. When diagnosis is confirmed proper treatment is indicated.
Download full-text PDF |
Source |
---|
Osteoporos Int
January 2025
Rush Biostatistics and Bioinformatics Core, Rush University, 600 S. Paulina St., Chicago, IL, 60612, USA.
Unlabelled: Dietary quality may be a factor in the progression of non-communicable, chronic diseases. This analysis of NHANES data demonstrates association between consumption of UPF and prevalence of osteoporosis and osteopenia in adults 50 years and older. UPF intake is an important consideration when recommending dietary patterns for optimum bone health PURPOSE: Declining bone mineral density in older adults can result in osteoporosis, leading to decreased physical function, quality of life, and increased risk of mortality.
View Article and Find Full Text PDFBMC Geriatr
January 2025
Department of Gerontology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Objectives: The obesity paradox is common among older adults at risk for various diseases. Although this paradox has also been observed in the association between obesity and osteoporosis, the available evidence remains controversial. This study aimed to investigate the association between obesity and OP risk in an older population.
View Article and Find Full Text PDFAustralas J Ageing
March 2025
Faculty of Nutrition, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.
Objective: Bone mineral density changes during the life span, rising rapidly during adolescence, plateauing around 30 years of age and decreasing in later years. Life events such as pregnancy and lactation temporarily reduce bone density, and their long-term effects on osteoporosis development are still unclear. This study aimed to analyse the association between pregnancy in adolescence and osteoporosis in aged women.
View Article and Find Full Text PDFMol Biol Rep
January 2025
Medical Sociology and Psychobiology, Department of Health and Physical Activity, University of Potsdam, 14469, Potsdam, Germany.
Background: Depression constitutes a risk factor for osteoporosis, but underlying molecular and cellular mechanisms are not fully understood. MiRNAs influence gene expression and are carried by extracellular vesicles (EV), affecting cell-cell communication.
Aims: (1) Identify the difference in miRNA expression between depressed patients and healthy controls; (2) Analyze associations of these miRNAs with bone turnover markers; (3) Analyze target genes of differentially regulated miRNAs and predict associated pathways regarding depression and bone metabolism.
Cochrane Database Syst Rev
January 2025
Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Rationale: Osteoporosis is an abnormal reduction in bone mass and bone deterioration, leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which inhibit bone resorption by interfering with the activity of osteoclasts (bone cells that break down bone tissue). This is an update of a Cochrane review first published in 2008.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!